REC: CardioClinics最新文献_第3页

Relationship between physical performance and health-related quality of life in patients with heart failure 心力衰竭患者的体能表现与健康相关生活质量之间的关系

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2023.10.008

{"title":"Relationship between physical performance and health-related quality of life in patients with heart failure","authors":"","doi":"10.1016/j.rccl.2023.10.008","DOIUrl":"10.1016/j.rccl.2023.10.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>This study aims to describe relationship between physical performance (PP) and health-related quality of life in patients with heart failure (HF).</p></div><div><h3>Methods</h3><p>This study used a cross-sectional design for data collection. Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used as a measurement tool, while the Five Times Sit-to-Stand Test (FTSST) was used to assess PP. The data were processed by Pearson correlation coefficient, <em>t</em>-test, one-way ANOVAs, and Hierarchical multiple regression.</p></div><div><h3>Results</h3><p>A total of 180 patients with HF participated in this study, with the mean age of respondents being 59.98 (11.86) years old. Among these respondents, 60% were male, with a mean PP of 9.56 (6.94)s and a mean MLHFQ of 43.14 (20.74). The results showed that MLHFQ had a significant correlation with HF medication (<em>r</em>  <.05), health status (<em>r</em>  <.01), FTSST (<em>r</em>  <.01), and MLHFQ was significantly associated with New York Heart Association (NYHA) Classification (<em>F</em>  <.001). There were three variables identified as predictors of MLHFQ, namely health status (<em>β</em>  =1.27), and FTSST (<em>β</em>  <!-->3.03), and were predicted to account for 31.1% of the variance in MLHFQ.</p></div><div><h3>Conclusions</h3><p>Efforts to increase PP from patients with HF can be an asset to improve health-related quality of life. Furthermore, health status and NYHA classifications are factors that can significantly affect health-related quality of life of patients with HF.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 3","pages":"Pages 177-183"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139292568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impacto de la guardia de cardiología en el tratamiento de reperfusión de los pacientes con IAMCEST en un centro de segundo nivel 值班心脏病学对二级中心 STEMI 患者再灌注治疗的影响。

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2023.11.002

{"title":"Impacto de la guardia de cardiología en el tratamiento de reperfusión de los pacientes con IAMCEST en un centro de segundo nivel","authors":"","doi":"10.1016/j.rccl.2023.11.002","DOIUrl":"10.1016/j.rccl.2023.11.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>The care of patients with cardiovascular disease by specialist in cardiology has shown better results in different spectrums. However, the presence of an on-call cardiologist is still rare in non-tertiary hospitals.</p></div><div><h3>Methods</h3><p>STEMI was recorded consecutively between 2006 and 2016 in a second level center. We analyzed and compared two periods: regional heart attack care network without a cardiology guard (2006-2011) and a second period (2012-2016) with both measures working.</p></div><div><h3>Results</h3><p>1524 patients were included, 47.2% after the start of cardiology shift. We observed an increase in primary angioplasty (34.3% to 75.7%, <em>P</em> <.001) as well as a reduction in door-to-balloon time of 64minutes (220 [IQR, 167-290] to 156 [IQR, 130-197], <em>P</em> <.001). This translates into a shorter hospital stay as well as a reduction in complications during hospitalization, mainly recurrent ischemia. Although there is a trend towards lower hospital mortality, mortality during follow-up did not change with the cardiology guard.</p></div><div><h3>Conclusions</h3><p>The presence of a cardiologist on call increases the number of patients reperfused, and shortens the time until it. This translates into a shorter hospital stay, as well as lower short-term mortality. Our results indicate that the creation of the cardiological guard brings additional benefit to the care network for patients with STEMI.</p><p>ClinicalTrials.gov identifier: <span><span>NCT02501070</span><svg><path></path></svg></span>.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 3","pages":"Pages 159-168"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ALCAPA, insuficiencia mitral e hipertensión pulmonar en adulto 成人 ALCAPA、二尖瓣反流和肺动脉高压

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2024.01.002

引用次数: 0

Solución percutánea para rotura del anillo aórtico tras TAVI transfemoral 经皮治疗经股动脉 TAVI 术后主动脉瓣环破裂的解决方案

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2024.01.005

引用次数: 0

Uso del sacubitrilo-valsartán pericirugía cardiaca: ¿es necesario retirarlo antes de la intervención? 心脏手术围手术期使用沙库比妥-缬沙坦：是否有必要在术前停药？

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2024.03.001

引用次数: 0

Pautas de optimización del tratamiento antiagregante tras un infarto agudo de miocardio 急性心肌梗死后抗血小板疗法优化指南

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2024.03.005

{"title":"Pautas de optimización del tratamiento antiagregante tras un infarto agudo de miocardio","authors":"","doi":"10.1016/j.rccl.2024.03.005","DOIUrl":"10.1016/j.rccl.2024.03.005","url":null,"abstract":"<div><p>Cardiovascular diseases are the leading cause of death in developed countries and account for more than a third of their healthcare costs. Acute coronary syndrome (ACS) is frequently one of the first manifestations of cardiovascular disease. There are important differences in post-ACS clinical management between centres and autonomous communities in Spain, as well as the clinical criteria used for applying the continuation of dual antiplatelet treatment (DAPT). Although there is an elevated number of potential candidates for prolonging DAPT beyond 1 year, recent data suggest that it is only applied in around one third of patients. Therefore, homogenizing treatment and follow-up criteria could contribute to reducing hospital stay and in-hospital mortality associated with ACS. To help this purpose, we propose a protocol of patient care management with practical applicability in our centres. This document also has the objective of synthesizing the recommendations of the clinical practice guidelines on post-ACS risk stratification and optimization of DAPT, proposing an algorithm to guide decision making. In line with the latest European clinical practice guidelines on ACS, we advise considering DAPT prolongation in patients who tolerated the treatment during the first year and have a significant residual thrombotic risk (moderate or high) without high bleeding risk. To assess bleeding risk, we recommend using the ARC-HBR scale, while the PRECISE-DAPT and DAPT scales can be used to integrate ischemic and haemorrhagic risk at discharge and 1 year after ACS, respectively.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 3","pages":"Pages 201-211"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2605153224000396/pdfft?md5=ce24590f1e4b173502b49e17acefd86b&pid=1-s2.0-S2605153224000396-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140759735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ivabradine for the treatment of vasovagal syncope 伊伐布雷定治疗血管迷走性晕厥

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2023.09.006

引用次数: 0

Streamlining same-day discharge for percutaneous coronary intervention: a single-center experience 简化经皮冠状动脉介入治疗的当日出院手续：单中心经验

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2023.12.004

{"title":"Streamlining same-day discharge for percutaneous coronary intervention: a single-center experience","authors":"","doi":"10.1016/j.rccl.2023.12.004","DOIUrl":"10.1016/j.rccl.2023.12.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Same-day discharge (SDD) can be considered for patients who traditionally required overnight stay (ONS) after percutaneous coronary intervention (PCI). The authors aimed to evaluate viability of SDD-PCI.</p></div><div><h3>Methods</h3><p>Retrospective single-center observational study of patients who underwent elective PCI. SDD patients were selected based on clinical, angiographic, and sociodemographic characteristics. Patient and procedure characteristics were collected from local databases, and SDD-PCI adverse events (all-cause mortality, acute coronary syndrome, stent thrombosis, reintervention, major bleeding, stroke, contrast-induced renal failure, vascular access complications) at 30-days were analyzed.</p></div><div><h3>Results</h3><p>This study included 147 patients, 76% males with a mean age of 66±10, that underwent elective PCI during the first year after implementation of SDD protocol. Most patients undergoing elective PCI were discharged the same day (<em>n</em>  =.01) and left ventricular dysfunction (17% vs 6%, <em>P</em>  =.01), more cases of multivessel PCI (24% vs 6%, <em>P</em>    =.02). There were no adverse events during the 30-day follow-up period of the patients treated in ambulatory regimen.</p></div><div><h3>Conclusions</h3><p>SDD-PCI is a safe procedure. Protocol implementation is key to guide interventional cardiologists in low-risk patient selection. The potential role in decreasing bed-shortage, hospital overcrowding, and healthcare costs is pivotal.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 3","pages":"Pages 184-190"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesidad y enfermedad cardiovascular y renal. Posicionamiento de las Asociaciones de Cardiología Preventiva, Cardiología Clínica e Insuficiencia Cardiaca de la SEC 肥胖与心血管疾病和肾脏疾病。SEC 预防心脏病学、临床心脏病学和心力衰竭协会的定位

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2024.04.003

引用次数: 0

Clinical outcomes associated with the use of sacubitril/valsartan in the perioperative period of patients undergoing cardiac surgery: a systematic review 心脏手术患者围手术期使用沙库比妥/缬沙坦的相关临床疗效：系统性综述

REC: CardioClinics Pub Date : 2024-07-01 DOI: 10.1016/j.rccl.2024.01.004

{"title":"Clinical outcomes associated with the use of sacubitril/valsartan in the perioperative period of patients undergoing cardiac surgery: a systematic review","authors":"","doi":"10.1016/j.rccl.2024.01.004","DOIUrl":"10.1016/j.rccl.2024.01.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Sacubitril/valsartan (SV) is recommended in patients with heart failure, especially in reduced ejection fraction. So far, the safety of its use in perioperative cardiac surgery is uncertain but given its mechanism of action and possible blood pressure lowering effect, some guidelines recommend discontinuation, without clear evidence. This systematic review aims to assess clinical outcomes of use SV in the perioperative period compared with never having used it or its withdrawal.</p></div><div><h3>Methods</h3><p>Systematic literature review in MedLine, Cochrane, EMBASE and LILACs of studies published in English and Spanish. We included randomized clinical trials and non-randomized studies evaluating adult patients undergoing cardiac surgery that compared the use of SV up to the day of surgery versus stopping or not starting it prior to the procedure. In-hospital and 30-day mortality, length of stay in general ward and intensive care unit stay, orotracheal intubation, postoperative vasoplegia and need for renal replacement therapy were assessed. Quality was assessed using the ROBINS tool.</p></div><div><h3>Results</h3><p>Three non-randomized studies were included, one single-arm. There were fewer cases of in-hospital and 30-day mortality in the group in which SV was not discontinued, with no statistically significant difference. There was no difference in length of hospital or intensive care unit stay, orotracheal intubation, need for renal replacement therapy, or frequency of postoperative vasoplegia (OR, 0.77; 95%CI, 0.23–2.98).</p></div><div><h3>Conclusions</h3><p>The current evidence is scarce and of low quality so a recommendation regarding the use of SV prior to cardiac surgery cannot be generated, further studies are required.</p></div>","PeriodicalId":36870,"journal":{"name":"REC: CardioClinics","volume":"59 3","pages":"Pages 169-176"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139828671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0